Sign in

BVXV on NASDAQ

BiondVax

Logo: http://www.biondvax.com/wp-content/uploads/2015/06/logo_100.png, Non-free logo, via Wikipedia3

Vaccine company, Israel

BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases. In collaboration with the Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax develops nanosized antibody (NanoAb) therapies for diseases such as COVID-19, asthma and psoriasis.2 Its shares trade on NASDAQ under the symbol BVXV.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

Jan 1, 2003Founded1

Compare with another stock.

See how the biggest companies compare on our leaderboards

BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases.2

The story

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and owns and operates a biologics manufacturing facility for housing its laboratories, production facilities and offices.

In 2017, their influenza vaccine was found in a Phase IIb trial to have "broad strain coverage."

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences – and the UMG to enter into a strategic collaboration for the development and commercialization of COVID-19 NanoAbs.

From Wikipedia’s article on BiondVax, shared under CC BY-SA 4.0.4

Timeline

  1. Jan 1, 2003Founded Founded1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4